The emerging role of the endocannabinoid system in endocrine regulation and energy balance

Endocrine Reviews

Volumn 27, Issue 1, 2006, Pages 73-100

  Pagotto, Uberto ^a   Marsicano, Giovanni ^b   Cota, Daniela ^c   Lutz, Beat ^b   Pasquali, Renato ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; 5 (4 BROMOPHENYL) 1 (2,4 DICHLOROPHENYL) 4 ETHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 9 AZA CANNABINOL; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CAPSAICIN; DELTA8 TETRAHYDROCANNABINOL; DRONABINOL; ENDOCANNABINOID; MELANOCORTIN RECEPTOR 4 ANTAGONIST; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N OLEOYLETHANOLAMINE; NEUROPROTECTIVE AGENT; PIRINIXIC ACID; RIMONABANT; SIBUTRAMINE; TESTOSTERONE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADIPOCYTE; ALZHEIMER DISEASE; ANXIETY DISORDER; APPETITE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DRUG MECHANISM; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOCRINE SYSTEM; ENERGY BALANCE; FERTILITY; FERTILIZATION IN VITRO; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GONADOTROPIN RELEASE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; IMMUNOCOMPETENT CELL; LIVER CELL; MOOD DISORDER; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; PROTEIN EXPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL BEHAVIOR; SKELETAL MUSCLE; SMOKING CESSATION; STRESS; WASTING SYNDROME;

ANIMALS; ENDOCANNABINOIDS; ENDOCRINE SYSTEM; ENERGY METABOLISM; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; OBESITY; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CANNABINOID;

EID: 32444440208     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2005-0009     Document Type: Review

References (333)

1. Peters H, Nahas GG 1999 A brief history of four millennia (B.C. 2000-A.D. 1974). In: Nahas GG, Sutin KM, Harvey D, Agurell S, eds. Marihuana and medicine. Totowa, NJ: Humana Press; 3-7
2. Gaoni Y, Mechoulam R 1964 Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647
3. Piomelli D 2003 The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884
4. De Petrocellis L, Cascio MG, Di Marzo V 2004 The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765-774
5. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z 1995 Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
7. Munro S, Thomas KL, Abu-Shaar M 1993 Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
9. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K 1995 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97
10. Di Marzo V, Melck D, Bisogno T, De Petrocellis L 1998 Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521-528
11. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E 2001 An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531
12. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M., Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B 2003 CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88
13. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E 2005 CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. J Cereb Blood Flow Metab 25:477-484
14. Cravatt BF, Lichtman AH 2004 The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61:149-160
15. van der Stelt M, Di Marzo V 2003 The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol 480:133-150
16. Wotjak CT 2005 Role of endogenous cannabinoids in cognition and emotionality. Mini Rev Med Chem 5:659-670
17. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B 2002 The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534
18. Varvel SA, Lichtman AH 2002 Evaluation of CB1 receptor knock-out mice in the Morris water maze. J Pharmacol Exp Ther 301:915-924
19. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N 2003 Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23:1398-1405
20. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H 2003 The cannabinoid system and immune modulation. J Leukoc Biol 74:486-496
21. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B 2004 The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202-1209
22. Mendizabal VE, Adler-Graschinsky E 2003 Cannabinoid system as a potential target for drug development in the treatment of cardiovascular disease. Curr Vasc Pharmacol 1:301-313
23. Bifulco M, Di Marzo V 2002 Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 8:547-550
24. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC 1990 Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932-1936
25. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG 2002 International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
26. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan Jr TP 2005 CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102:3093-3098
27. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G 2005 Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133-145
28. van der Stelt M, Trevisani M, Vellani V, De Petrocellis L, Schiano-Moriello A, Campi B, McNaughton P, Geppetti P, Di Marzo V 2005 Anandamide acts as an intracellular messenger amplifying Ca(2+) influx via TRPV1 channels. EMBO J 24:3026-3037
29. Maingret F, Patel AJ, Lazdunski M, Honore E 2001 The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1. EMBO J 20:47-54
30. Freund TF, Katona I, Piomelli D 2003 Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066
31. Mo FM, Offertaler L, Kunos G 2004 Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489:21-27
32. Baker D, Pryce G, Davis WL, Hiley CR, In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci, in press
33. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC 1991 Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583
34. Matsuda LA, Bonner TI, Lolait SJ 1993 Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535-550
35. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M 1994 Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63:637-652
36. Marsicano G, Lutz B 1999 Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11:4213-4225
37. Glass M, Dragunow M, Faull RL 1997 Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299-318
38. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM 1998 Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393-411
39. Pettit DA, Harrison MP, Olson JM, Spencer RF, Cabral GA 1998 Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51:391-402
40. Egertova M, Cravatt BF, Elphick MR 2003 Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119:481-496
41. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, Freund TF 1999 Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544-4558
42. 35S]thio]-triphosphate binding. Proc Natl Acad Sci USA 92:7242-7246
43. Breivogel CS, Childers SR 1998 The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 5:417-431
44. Katona I, Sperlagh B, Magloczky Z, Santha E, Kofalvi A, Czirjak S, Mackie K, Vizi ES, Freund TF 2000 GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100:797-804
45. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U 2003 Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289-301
46. Wenger T, Moldrich G, Furst S 2003 Neuromorphological background of cannabis addiction. Brain Res Bull 61:125-128
47. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B 2005 Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25:2874-2884
48. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273:16865-16873
49. Gonzalez S, Bisogno T, Wenger T, Manzanares J, Milone A, Berrendero F, Di Marzo V, Ramos JA, Fernandez-Ruiz JJ 2000 Sex steroid influence on cannabinoid CB1 receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun 270:260-266
50. Wenger T, Fernandez-Ruiz JJ, Ramos JA 1999 Immunocytochemical demonstration of CB1 cannabinoid receptors in the anterior lobe of the pituitary gland. J Neuroendocrinol 11:873-878
51. Cesa R, Guastalla A, Cottone E, Mackie K, Beltramo M, Franzoni MF 2002 Relationships between CB1 cannabinoid receptors and pituitary endocrine cells in Xenopus laevis: an immunohistochemical study. Gen Comp Endocrinol 125:17-24
52. Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Gruebler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V, Lutz B, Stalla GK 2001 Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab 86:2687-2696
53. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS, Oyesiku NM 2001 Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 86:3097-3107
54. Gonzalez S, Manzanares J, Berrendero F, Wenger T, Corchero J, Bisogno T, Romero J, Fuentes JA, Di Marzo V, Ramos JA, Fernandez-Ruiz JJ 1999 Identification of endocannabinoids and cannabinoid CB1 receptor mRNA in the pituitary gland. Neuroendocrinology 70:137-145
55. Buckley NE, Hansson S, Harta G, Mezey E 1998 Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience 82:1131-1149
56. Porcella A, Marchese G, Casu MA, Rocchitta A, Lai ML, Gessa GL, Pani L 2002 Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. Eur J Endocrinol 147:255-261
57. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P 1995 Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61
58. Cota D, Marsicano G, Tschoep M, Gruebler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431
59. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P 2003 The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914
60. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J 2005 Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843
61. Liu YL, Connoley IP, Wilson CA, Stock MJ 2005 Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes Relat Metab Disord 29:183-187
62. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G 2005 Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305
63. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF 2005 Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 41:1085-1095
64. Pertwee RG 2001 Cannabinoids and the gastrointestinal tract. Gut 48:859-867
65. Buyse M, Ovesjo ML, Goiot H, Guilmeau S, Peranzi G, Moizo L, Walker F, Lewin MJ, Meister B, Bado A 2001 Expression and regulation of leptin receptor proteins in afferent and efferent neurons of the vagus nerve. Eur J Neurosci 14:64-72
66. Burdyga G, Lal S, Spiller D, Jiang W, Thompson D, Attwood S, Saeed S, Grundy D, Varro A, Dimaline R, Dockray GJ 2003 Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 124:129-139
67. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ 2004 Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24:2708-2715
68. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM 2004 Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. Br J Nutr 92:757-761
69. van der Lely AJ, Tschoep M, Heiman ML, Ghigo E 2004 Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426-457
70. Gerard CM, Mollereau C, Vassart G, Parmentier M 1991 Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279:129-134
71. Wenger T, Ledent C, Csernus V, Gerendai I 2001 The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem Biophys Res Commun 284:363-368
72. Maccarrone M, Cecconi S, Rossi G, Battista N, Pauselli R, Finazzi-Agro A 2003 Anandamide activity and degradation are regulated by early postnatal aging and follicle-stimulating hormone in mouse Sertoli cells. Endocrinology 144:20-28
73. Chang MC, Berkery D, Schuel R, Laychock SG, Zimmerman AM, Zimmerman S, Schuel H 1993 Evidence for a cannabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 36:507-516
74. Schuel H, Burkman LJ, Lippes J, Crickard K, Forester E, Piomelli D, Giuffrida A 2002 N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids 121:211-227
75. Rossato M, Ion Popa F, Ferigo M, Clari G, Foresta C 2005 Human sperm express cannabinoid receptor CB1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function. J Clin Endocrinol Metab 90:984-991
76. 9-tetrahydrocannabinol in cultured rat granulosa cells. Toxicol Appl Pharmacol 118:53-57
77. Das SK, Paria BC, Chakraborty I, Dey SK 1995 Cannabinoid ligand-receptor signaling in the mouse uterus. Proc Natl Acad Sci USA 92:4332-4336
78. Dennedy MC, Friel AM, Houlihan DD, Broderick VM, Smith T, Morrison JJ 2004 Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol 190:2-9
79. Wang H, Guo Y, Wang D, Kingsley PJ, Marnett LJ, Das SK, DuBois RN, Dey SK 2004 Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med 10:1074-1080
80. Paria BC, Das SK, Dey SK 1995 The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci USA 92:9460-9464
81. Park B, Gibbons HM, Mitchell MD, Glass M 2003 Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta 24:990-995
82. Mackie K 19 August 2005 Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 10.1146/annurev.pharmtox.46.120604.141254
83. Howlett AC 2004 Efficacy in CB1 receptor-mediated signal transduction. Br J Pharmacol 142:1209-1218
84. Diaz-Laviada I, Ruiz-Llorente L 2005 Signal transduction activated by cannabinoid receptors. Mini Rev Med Chem 5:619-630
85. Fowler CJ, Holt S, Nilsson O, Jonsson KO, Tiger G, Jacobsson SO 2005 The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81:248-262
86. Glass M, Felder CC 1997 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333
87. Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M 2005 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor crosstalk? Mol Pharmacol 67:1697-1704
88. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P 2003 Hypersensitization of the orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278:23731-23737
89. Devlin MG, Christopoulos A 2002 Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 80:1095-1102
90. Howlett AC 2002 The cannabinoid receptors. Prostaglandins Other Lipid Mediat 68- 69:619-631
91. Bradshaw HB, Walker JM 2005 The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol 144:459-465
92. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R 2001 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665
93. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC 2002 Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020-1024
94. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V 2002 An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400-8405
95. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, Kendall DA 2004 Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253-262
96. Giang DK, Cravatt BF 1997 Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 94:2238-2242
97. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D 2002 Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824
98. Dinh TP, Kathuria S, Piomelli D 2004 RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 66:1260-1264
99. Barnett-Norris J, Lynch D, Reggio PH 2005 Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci 77:1625-1639
100. McFarland MJ, Barker EL 2004 Anandamide transport. Pharmacol Ther 104:117-135
101. Cravatt BF, Lichtman AH 2003 Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7:469-475
102. Di Marzo V, Bifulco M, De Petrocellis L 2004 The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784
103. Di S, Malcher-Lopes R, Halmos KC, Tasker JG 2003 Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23:4850-4857
104. 2+ dependency for triggering retrograde endocannabinoid signal. Neuron 45:257-268
105. McFarland MJ, Porter AC, Rakhshan FR, Rawat DS, Gibbs RA, Barker EL 2004 A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. J Biol Chem 279:41991-41997
106. Wilson RI, Nicoll RA 2002 Endocannabinoid signaling in the brain. Science 296:678-682
107. Alger BE 2002 Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68:247-286
108. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL 2004 Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53-62
109. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL, Pistis M 2004 Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707-10715
110. Bacci A, Huguenard JR, Prince DA 2004 Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids. Nature 431:312-316
111. Stella N 2004 Cannabinoid signaling in glial cells. Glia 48:267-277
112. Chevaleyre V, Castillo PE 2004 Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron 43:871-881
113. Gerdeman G, Lovinger DM 2001 CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 85:468-471
114. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W, Rammes G 2004 Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24:9953-9961
115. Mechoulam R, Spatz M, Shohami E 2002 Endocannabinoids and neuroprotection. Sci STKE 2002:RE5
116. Mechoulam R, Panikashvili D, Shohami E 2002 Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8:58-61
117. Parker LA, Mechoulam R, Schlievert C 2002 Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13:567-570
118. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E 1999 HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96:14228-14233
119. Calignano A, La Rana G, Giuffrida A, Piomelli D 1998 Control of pain initiation by endogenous cannabinoids. Nature 394:277-281
120. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D 1997 Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097
121. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V 2000 Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52-56
122. de Lago E, Fernandez-Ruiz JJ, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA 2002 UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 449:99-103
123. Lange JH, Kruse CG 2004 Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Devel 7:498-506
124. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 307:331-338
125. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrié P, Breliere JC, Le Fur G 1994 SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244
126. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Perio A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrié P, Le Fur G 2004 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H- pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 310:905-914
127. Lan R, Gatley J, Lu Q, Fan P, Fernando SR, Volkow ND, Pertwee R, Makriyannis A 1999 Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci 1:E4
128. Felder CC, Joyce KE, Briley EM, Glass M, Mackie KP, Fahey KJ, Cullinan GJ, Hunden DC, Johnson DW, Chaney MO, Koppel GA, Brownstein M 1998 LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 284:291-297
129. Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, Keizer HG, Tipker K, McCreary AC, Veerman W, Wals HC, Stork B, Verveer PC, den Hartog AP, de Jong NM, Adolfs TJ, Hoogendoorn J, Kruse CG 2004 Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists. J Med Chem 47:627-643
130. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA 2001 Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322-328
131. Dutta AK, Sard H, Ryan W, Razdan RK, Compton DR, Martin BR 1994 The synthesis and pharmacological evaluation of the cannabinoid antagonist SR141716A. Med Chem Res 5:54-62
132. Pertwee RG 2005 Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324
133. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P 1997 A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339
134. Harmon J, Aliapoulios MA 1972 Gynecomastia in marihuana users. N Engl J Med 287:936
135. Murphy LL, Munoz RM, Adrian BA, Villanua MA 1998 Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 5:432-446
136. 9-tetrahydrocannabinol on the hypothalamo-hypophyseal-adrenal axis of rats. Eur J Pharmacol 12:382-384
137. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M 1996 Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21,38,C α MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 276:56-64
138. Corchero J, Fuentes JA, Manzanares J 1999 Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat. Life Sci 64:905-911
139. Weidenfeld J, Feldman S, Mechoulam R 1994 Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary- adrenal axis in the rat. Neuroendocrinology 59:110-112
140. Wenger T, Jamali KA, Juaneda C, Leonardelli J, Tramu G 1997 Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem Biophys Res Commun 237:724-728
141. Kubena RK, Barry HI 1970 Interactions of D-tetrahydrocannabinol with barbiturates and methamphetamine. J Pharmacol Exp Ther 173:94-100
142. Barna I, Zelena D, Arszovszki AC, Ledent C 2004 The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knock-out mice. Life Sci 75:2959-2970
143. Navarro M, Hernandez E, Munoz RM, Del Arco I, Villanua MA, Carrera MR, Rodriguez de Fonseca F 1997 Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496
144. Arevalo C, de Miguel R, Hernandez-Tristan R 2001 Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70:123-131
145. De Kloet ER 2003 Hormones, brain and stress. Endocr Regul 37:51-68
146. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ 2004 Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145:5431-5438
147. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D 2003 Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81
148. Uriguen L, Perez-Rial S, Ledent C, Palomo T, Manzanares J 2004 Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46:966-973
149. 9-tetrahydrocannabinol administration in man. J Clin Endocrinol Metab 42:938-941
150. 9-THC on growth hormone and ACTH secretion in rats. Life Sci 15:329-338
151. 8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats. Eur J Pharmacol 344:77-86
152. Dalterio SL, Michael SD, Macmillan BT, Bartke A 1981 Differential effects of cannabinoid exposure and stress on plasma prolactin, growth hormone and corticosterone levels in male mice. Life Sci 28:761-766
153. 9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology 47:498-503
154. 9-tetrahydrocannabinol to stimulate somatostatin release and block that of luteinizing hormone-releasing hormone by suppression of the release of prostaglandin E2. Proc Natl Acad Sci USA 87:10063-10066
155. Tucci SA, Rogers EK, Korbonits M, Kirkham TC 2004 The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520-523
156. Lomax P 1970 The effect of marihuana on pituitary-thyroid activity in the rat. Agents Actions 1:252-257
157. 9-tetrahydrocannabinol on serum thyrotropin levels in the rat. Pharmacol Biochem Behav 20:547-550
158. Miras CJ 1965 Some aspects of cannabis action. In: Wolstenhome GE, Knight J, eds. Hashish: its chemistry and pharmacology. Boston: Brown; 37-52
159. 9-tetrahydrocannabinol (THC): involvement of serotonergic and dopaminergic pathways. Endocrinology 103:452-457
160. 9- tetrahydrocannabinol in nonhuman primates. Fertil Steril 32:571-575
161. 9- Tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect. Endocrinology 109:876-880
162. Scorticati C, Mohn C, De Laurentiis A, Vissio P, Fernandez SJ, Seilicovich A, McCann SM, Rettori V 2003 The effect of anandamide on prolactin secretion is modulated by estrogen. Proc Natl Acad Sci USA 100:2134-2139
163. 9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. Brain Res 841:114-122
164. 9-tetrahydrocannabinol. J Endocrinol 63:415-416
165. 9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 52:316-321
166. 9-tetrahydrocannabinol action. Pharmacol Biochem Behav 40:603-607
167. Fernandez-Ruiz JJ, Munoz RM, Romero J, Villanua MA, Makriyannis A, Ramos JA 1997 Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem Pharmacol 53:1919-1927
168. Rodriguez de Fonseca F, Cebeira M, Fernandez-Ruiz JJ, Navarro M, Ramos JA 1991 Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons. Neuroscience 43:713-723
169. 9-tetrahydrocannabinol on tuberoinfundibular dopamine activity, anterior pituitary sensitivity to dopamine and prolactin release vary as a function of estrous cycle. Neuroendocrinology 58:280-286
170. 9- tetrahydrocannabinol antagonism of the anterior pituitary response to estradiol in immature female rats. Steroids 56:97-102
171. Ho BY, Stadnicka A, Prather PL, Buckley AR, Current LL, Bosnjak ZJ, Kwok WM 2000 Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. Endocrinology 141:1675-1685
172. Wenger T, Toth BE, Martin BR 1995 Effects of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci 56:2057-2063
173. 9-tetrahydrocannabinol) on the secretion of luteinizing hormone in the ovariectomized rhesus monkey. Am J Obstet Gynecol 128:635-642
174. 9-tetrahydrocannabinol suppression of episodic luteinizing hormone secretion in the ovariectomized rat. Endocrinology 102:1808-1814
175. 9-tetrahydrocannabinol (THC) on female reproductive function. Adv Biosci 22- 23:449-467
176. 9-tetrahydrocannabinol during the follicular phase of the rhesus monkey (Macaca mulatta). J Clin Endocrinol Metab 52:50-55
177. 9-tetrahydrocannabinol on primate menstrual cycle. Science 219:1453-1455
178. Mendelson JH, Cristofaro P, Ellingboe J, Benedikt R, Mello NK 1985 Acute effects of marihuana on luteinizing hormone in menopausal women. Pharmacol Biochem Behav 23:765-768
179. Mendelson JH, Mello NK, Ellingboe J, Skupny AS, Lex BW, Griffin M 1986 Marihuana smoking suppresses luteinizing hormone in women. J Pharmacol Exp Ther 237:862-866
180. Mendelson JH, Mello NK 1999 Marihuana effects on pituitary and gonadal hormones in women. In: Nahas GG, Sutin KM, Harvey D, Agurell S, eds. Marihuana and medicine. Totowa, NJ: Humana Press; 385-392
181. Shen M, Piser TM, Seybold VS, Thayer SA 1996 Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322-4334
182. 9- tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol Biochem Behav 42:269-275
183. de Miguel R, Romero J, Munoz RM, Garcia-Gil L, Gonzalez S, Villanua MA, Makriyannis A, Ramos JA, Fernandez-Ruiz JJ 1998 Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic γ-aminobutyric acid (GABA) inputs. Biochem Pharmacol 56:1331-1338
184. 9-tetrahydrocannabinol on serum luteinizing hormone and prolactin in rats. Subst Alcohol Actions Misuse 4:347-353
185. 9- tetrahydrocannabinol. Neuroendocrinology 65:446-452
186. Maldonado R 2002 Study of cannabinoid dependence in animals. Pharmacol Ther 95:153-164
187. Rodriguez de Fonseca F, Cebeira M, Ramos JA, Martin M, Fernandez-Ruiz JJ 1994 Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci 54:159-170
188. 9-Tetrahydrocannabinol stimulates receptive and proceptive sexual behaviors in female hamsters. Pharmacol Biochem Behav 14:745-747
189. 9-tetrahydrocannabinol modulation of sexual receptivity in female rats. Proc Natl Acad Sci USA 98:1249-1254
190. Stella N 2001 How might cannabinoids influence sexual behavior? Proc Natl Acad Sci USA 98:793-795
191. Schmid PC, Paria BC, Krebsbach RJ, Schmid HH, Dey SK 1997 Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 94:4188-4192
192. Paria BC, Ma W, Andrenyak DM, Schmid PC, Schmid HH, Moody DE, Deng H, Makriyannis A, Dey SK 1998 Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biol Reprod 58:1490-1495
193. Wang J, Paria BC, Dey SK, Armant DR 1999 Stage-specific excitation of cannabinoid receptor exhibits differential effects on mouse embryonic development. Biol Reprod 60:839-844
194. Paria BC, Dey SK 2000 Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 108:211-220
195. Maccarrone M, Finazzi-Agro A 2004 Anandamide hydrolase: a guardian angel of human reproduction? Trends Pharmacol Sci 25:353-357
196. Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agro A 2000 Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355:1326-1329
197. Maccarrone M, Falciglia K, Di Rienzo M, Finazzi-Agro A 2002 Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids 66:309-317
198. Paria BC, Deutsch DD, Dey SK 1996 The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol Reprod Dev 45:183-192
199. Wang H, Matsumoto H, Guo Y, Paria BC, Roberts RL, Dey SK 2003 Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. Proc Natl Acad Sci USA 100:14914-14919
200. Helliwell RJ, Chamley LW, Blake-Palmer K, Mitchell MD, Wu J, Kearn CS, Glass M 2004 Characterization of the endocannabinoid system in early human pregnancy. J Clin Endocrinol Metab 89:5168-5174
201. Kolodny RC, Masters WH, Kolodner RM, Toro G 1974 Depression of plasma testosterone levels after chronic intensive marihuana use. N Engl J Med 290:872-874
202. 9-tetrahydrocannabinol on the hypothalamic-pituitary-gonadal system in the maturing male rat. J Endocrinol 68:43P-44P
203. Harclerode J, Nyquist SE, Nazar B, Lowe D 1978 Effects of cannabis on sex hormones and testicular enzymes of the rodent. Adv Biosci 22- 23:395-405
204. Dixit VP, Sharma VN, Lohiya NK 1974 The effect of chronically administered cannabis extract on the testicular function of mice. Eur J Pharmacol 26:111-114
205. Wenger T, Fragkakis G, Giannikou P, Probonas K, Yiannikakis N 1997 Effects of anandamide on gestation in pregnant rats. Life Sci 60:2361-2371
206. 2+)-dependent transacylase and phosphodiesterase activities. Biochem Biophys Res Commun 218:113-117
207. Merari A, Barak A, Plaves M 1973 Effects of 1(2)-tetrahydrocannabinol on copulation in the male rat. Psychopharmacologia 28:243-246
208. Schuel H, Goldstein E, Mechoulam R, Zimmerman AM, Zimmerman S 1994 Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. Proc Natl Acad Sci USA 91:7678-7682
209. Schuel H, Burkman LJ, Lippes J, Crickard K, Mahony MC, Giuffrida A, Picone RP, Makriyannis A 2002 Evidence that anandamide-signaling regulates human sperm functions required for fertilization. Mol Reprod Dev 63:376-387
210. Bisogno T, Ventriglia M, Milone A, Mosca M, Cimino G, Di Marzo V 1997 Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Biochim Biophys Acta 1345:338-348
211. Hall W, Solowij N 1998 Adverse effects of cannabis. Lancet 352:1611-1616
212. De Petrocellis L, Melck D, Bisogno T, Milone A, Di Marzo V 1999 Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 92:377-387
213. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R 2001 Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419:207-214
214. Abel EL, McMillan DE, Harris LS 1972 Tolerance to the behavioral and hypothermic effects of 1-9-tetrahydrocannabinol in neonatal chicks. Experientia 28:1188-1189
215. Dewey WL, Jenkins J, O'Rourke T, Harris LS 1972 The effects of chronic administration of trans-9-tetrahydrocannabinol on behavior and the cardiovascular system of dogs. Arch Int Pharmacodyn Ther 198:118-131
216. Huy ND, Gailis L, Roy PE 1974 Effects on dogs of 3 months of inhalation of marijuana and tobacco smoke. Union Med Can 103:65-71
217. Thompson GR, Rosenkrantz H, Schaeppi UH, Braude MC 1973 Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 25:363-372
218. Vaupel DB, Morton EC 1982 Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens. Pharmacol Biochem Behav 17:539-545
219. 9-THC) in guinea-pigs. Int J Clin Pharmacol Biopharm 12:284-289
220. Geber WF, Schramm LC 1969 Effect of marihuana extract on fetal hamsters and rabbits. Toxicol Appl Pharmacol 14:276-282
221. Scheckel CL, Boff E, Dahlen P, Smart T 1968 Behavioral effects in monkeys of racemates of two biologically active marijuana constituents. Science 160:1467-1469
222. Grunfeld Y, Edery H 1969 Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacologia 14:200-210
223. 9-Trans-tetrahydrocannabinol in pigeons: tolerance to the behavioral effects. Science 169:501-503
224. 9-transtetrahydrocannabinol (THC) administered subcutaneously for 13 days to female rabbits. J Toxicol Environ Health 1:769-776
225. Carlini EA, Kramer C 1965 Effects of Cannabis sativa (marihuana) on maze performance of the rat. Psychopharmacologia 7:175-181
226. Borgen LA, Davis WM, Pace HB 1971 Effects of synthetic 9 -tetrahydrocannabinol on pregnancy and offspring in the rat. Toxicol Appl Pharmacol 20:480-486
227. Gonzalez SC, Karniol IG, Carlini EL 1972 Effects of Cannabis sativa extract on conditioned fear. Behav Biol 7:83-94
228. Rating D, Broermann I, Honecker H, Kluwe S, Coper H 1972 Effect of subchronic treatment with (-)8-trans-tetrahydrocannabinol (8-THC) on food intake, body temperature, hexobarbital sleeping time and hexobarbital elimination in rats. Psychopharmacologia 27:349-357
229. Graham JD, Li DM 1973 Cardiovascular and respiratory effects of cannabis in cat and rat. Br J Pharmacol 49:1-10
230. 9-tetrahydrocannabinol in the spontaneously hypertensive rat. Proc Soc Exp Biol Med 142:58-60
231. 9-tetrahydrocannabinol actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 38:329-338
232. 9-THC on food and water intake of deprivation experienced rats. Behav Biol 11:395-401
233. 9-tetrahydrocannabinol on food intake by rats. Psychopharmacologia 39:213-222
234. Johansson JO, Jarbe TU, Henriksson BG 1975 Acute and subchronic influences of tetrahydrocannabinols on water and food intake, body weight, and temperature in rats. TIT J Life Sci 5:17-27
235. Sofia RD, Knobloch LC 1976 Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats. Pharmacol Biochem Behav 4:591-599
236. 9- tetrahydrocannabinol on feeding patterns and activity of obese and lean Zucker rats. Behav Biol 23:112-117
237. 9-tetrahydrocannabinol. Pharmacol Biochem Behav 9:619-630
238. Anderson-Baker WC, McLaughlin CL, Baile CA 1979 Oral and hypothalamic injections of barbiturates, benzodiazepines and cannabinoids and food intake in rats. Pharmacol Biochem Behav 11:487-491
239. 9-tetrahydrocannabinol in rats. Psychopharmacology (Berl) 67:195-202
240. Milano WC, Wild KD, Hui YZ, Hubbell CL, Reid LD 1988 PCP, THC, ethanol, and morphine and consumption of palatable solutions. Pharmacol Biochem Behav 31:893-897
241. 9- tetrahydrocannabinol on hypothalamically induced feeding. Psychopharmacology (Berl) 103:172-176
242. McLaughlin CL, Baile CA, Bender PE 1979 Cannabinols and feeding in sheep. Psychopharmacology (Berl) 64:321-323
243. Van Den Broek GW, Robertson J, Keim DA, Baile CA 1979 Feeding and depression of abomasal secretion in sheep elicited by elfazepam and 9-aza-cannabinol. Pharmacol Biochem Behav 11:51-56
244. Rosenkrantz H, Braude M 1974 Acute, subacute and 23-day chronic marihuana inhalation toxicities in the rat. Toxicol Appl Pharmacol 28:428-441
245. Abel EL 1975 Cannabis: effects on hunger and thirst. Behav Biol 15:255-281
246. 9-THC. Physiol Behav 65:343-346
247. 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71:333-340
248. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG 1976 Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl) 49:79-84
249. Foltin RW, Brady JV, Fischman MW 1986 Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25:577-582
250. Foltin RW, Brady JV, Fischman MW, Emurian CS, Dominitz J 1987 Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend 20:87-93
251. Cat LK, Coleman RL 1994 Treatment for HIV wasting syndrome. Ann Pharmacother 28:595-597
252. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV 1997 Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7-14
253. Gorter RW 1999 Cancer cachexia and cannabinoids. Forsch Komplementarmed 6(Suppl 3):21-22
254. 9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 293:795-797
255. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ 1997 Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12:913-919
256. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG 1991 Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40:695-700
257. Gorter R, Seefried M, Volberding P 1992 Dronabinol effects on weight in patients with HIV infection. AIDS 6:127
258. Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K, Evans TG 1993 Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 27:827-831
259. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV 1995 Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97
260. Grinspoon S, Carr A 2005 Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48-62
261. Williams CM, Kirkham TC 1999 Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143:315-317
262. Kirkham TC, Williams CM 2001 Endogenous cannabinoids and appetite. Nutr Res Reviews 14:65-86
263. Hao S, Avraham Y, Mechoulam R, Berry EM 2000 Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392:147-156
264. Kirkham TC, Williams CM, Fezza F, Di Marzo V 2002 Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557
265. 9-THC and anandamide. Physiol Behav 76:241-250
266. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrié P, Le Fur G 1997 Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106
267. Gallate JE, McGregor IS 1999 The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716. Psychopharmacology (Berl) 142:302-308
268. Freedland CS, Poston JS, Porrino LJ 2000 Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol Biochem Behav 67:265-270
269. Simiand J, Keane M, Keane PE, Soubrié P 1998 SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179-181
270. Verty AN, McGregor IS, Mallet PE 2004 Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neurosci Lett 354:217-220
271. 9-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berl) 165:370-377
272. Chaperon F, Soubrié P, Puech AJ, Thiebot MH 1998 Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135:324-332
273. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M 1999 Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404
274. Arnold JC, Hunt GE, McGregor IS 2001 Effects of the cannabinoid receptor agonist CP55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci 70:97-108
275. Gardner EL, Vorel SR 1998 Cannabinoid transmission and reward-related events. Neurobiol Dis 5:502-533
276. Spanagel R, Weiss F 1999 The dopamine hypothesis of reward: past and current status. Trends Neurosci 22:521-527
277. Hernandez L, Hoebel BG 1988 Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by microdialysis. Life Sci 42:1705-1712
278. Rusk IN, Cooper SJ 1989 The selective dopamine D1 receptor agonist SK&F 38393: its effects on palatability- and deprivation-induced feeding, and operant responding for food. Pharmacol Biochem Behav 34:17-22
279. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, Di Marzo V 1999 Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256:377-380
280. Hermann H, Marsicano G, Lutz B 2002 Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451-460
281. Berridge KC, Robinson TE 1998 What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369
282. 9- tetrahydrocannabinol. Brain Res 1020:188-195
283. Corchero J, Manzanares J, Fuentes JA 2004 Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 16:159-172
284. Bakshi VP, Kelley AE 1993 Feeding induced by opioid stimulation of the ventral striatum: role of opiate receptor subtypes. J Pharmacol Exp Ther 265:1253-1260
285. Jackson HC, Sewell RD 1985 Are D-opioid receptors involved in the regulation of food and water intake? Neuropharmacology 24:885-888
286. Verty AN, Singh ME, McGregor IS, Mallet PE 2003 The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology (Berl) 168:314-323
287. Kirkham TC, Williams CM 2001 Synergistic effects of opioid and cannabinoid antagonists on food intake. Psychopharmacology (Berl) 153:267-270
288. Rowland NE, Mukherjee M, Robertson K 2001 Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl) 159:111-116
289. Vickers SP, Dourish CT, Kennett GA 2001 Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors. Neuropharmacology 41:200-209
290. Vettor R, Serra R, Fabris R, Pagano C, Federspil G 2005 Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 28:942-949
291. Flier JS 2004 Obesity wars: molecular progress confronts an expanding epidemic. Cell 116:337-350
292. Erickson JC, Clegg KE, Palmiter RD 1996 Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381:415-421
293. Wynne K, Stanley S, McGowan B, Bloom S 2005 Appetite control. J Endocrinol 184:291-318
294. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G 2001 Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825
295. Hanus L, Avraham Y, Ben-Shushan D, Zolotarev O, Berry EM, Mechoulam R 2003 Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 983:144-151
296. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G 2002 Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 952:232-238
297. Jamshidi N, Taylor DA 2001 Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154
298. Horvath TL 2003 Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 112:323-326
299. Verty AN, McFarlane JR, McGregor IS, Mallet PE 2004 Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145:3224-3231
300. Dallman MF, Akana SF, Strack AM, Scribner KS, Pecoraro N, La Fleur SE, Houshyar H, Gomez F 2004 Chronic stress-induced effects of corticosterone on brain: direct and indirect. Ann NY Acad Sci 1018:141-150
301. Verty AN, McFarlane JR, McGregor IS, Mallet PE 2004 Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 47:593-603
302. Seeley RJ, York DA 2005 Fuel sensing and the central nervous system (CNS): implications for the regulation of energy balance and the treatment for obesity. Obes Rev 6:259-265
303. Loftus TM, Jaworsky DE, Frehywot GL, Townsend CA, Ronnett GV, Lane MD, Kuhajda FP 2000 Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 288:2379-2381
304. Kim EK, Miller I, Landree LE, Borisy-Rudin FF, Brown P, Tihan T, Townsend CA, Witters LA, Moran TH, Kuhajda FP, Ronnett GV 2002 Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment. Am J Physiol Endocrinol Metab 283:E867-E879
305. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL 1998 Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:L113-L117
306. Ravinet-Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P 2004 CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648
307. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrié P, Le Fur G, Galiegue S, Casellas P 2005 The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569
308. Chandran M, Phillips SA, Ciaraldi T, Henry RR 2003 Adiponectin: more than just another fat cell hormone? Diabetes Care 26:2442-2450
309. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, Herbert JM 2005 The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7:65-72
310. Ravinet-Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrié P 2003 Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353
311. Hildebrandt AL, Kelly-Sullivan DM, Black SC 2003 Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 462:125-132
312. Shearman LP, Zhou D, Rosko KM, Camacho RE, Stribling D, MacIntyre D, Strack AM, Multiple day CB1R inverse agonist effects on hypothalamic gene expression and energy balance in diet-induced obese mice. Proc 34th Annual Meeting of the Society for Neuroscience, San Diego, CA, 2004 (Abstract 76.4)
313. Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG 2001 The cannabinoid CB1 receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus. Eur J Pharmacol 426:R3-R4
314. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M 2005 Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-25201
315. Schwabe RF 2005 Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. Hepatology 42:959-961
316. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F 2002 A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617
317. Rodriguez de Fonseca F, Navarro M, Gomez R, Escuredo L, Nava F, Fu J, Murillo-Rodriguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S, Gall C, Piomelli D 2001 An anorexic lipid mediator regulated by feeding. Nature 414:209-212
318. Fu J, Gaetani S, Oveisi F, LoVerme J, Serrano A, Rodriguez de Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D 2003 Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425:90-93
319. Proulx K, Cota D, Castaneda TR, Tschoep M, D'Alessio DA, Tso P, Woods SC, Seeley RJ 2005 Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity. Am J Physiol Regul Integr Comp Physiol 289:R729-R737
320. Guzman M, LoVerme J, Fu J, Oveisi F, Blazquez C, Piomelli D 2004 Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α). J Biol Chem 279:27849-27854
321. Oveisi F, Gaetani S, Eng KT, Piomelli D 2004 Oleoylethanolamide inhibits food intake in free-feeding rats after oral administration. Pharmacol Res 49:461-466
322. Nielsen MJ, Petersen G, Astrup A, Hansen HS 2004 Food intake is inhibited by oral oleoylethanolamide. J Lipid Res 45:1027-1029
323. Fernandez JR, Allison DB 2004 Rimonabant Sanofi-Synthelabo. Curr Opin Investig Drugs 5:430-435
324. Meltzer HY, Arvanitis L, Bauer D, Rein W 2004 Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975-984
325. Anthenelli RM, Despres JP, Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial (smoking cessation in smokers motivated to quit). Proc Annual Meeting of the American College of Cardiology, New Orleans, LA, 2004
326. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP 2004 Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6:501-508
327. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, for the RIO-Europe Study Group 2005 Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397
328. 2002 Third Report of the National Cholesterol Educational Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
329. Pagotto U, Pasquali R 2005 Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 365:1363-1364
330. Sipe JC, Waalen J, Gerber A, Beutler E 2005 Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes Relat Metab Disord 29:755-759
331. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L
332. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA 2002 Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22:9771-9775
333. Despres JP, Golay A, Sjostrum L, for the Rimonabant in Obesity-Lipids Study Group 2005 Effects of rimonabant on body weight and the metabolic syndrome in overweight patients. N Engl J Med 353:2121-2134